JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

A recent institutional experience with renovascular hypertension.

American Surgeon 1996 March
During and 8-year period, 51 patients with renovascular hypertension were evaluated. Etiologies of renovascular disease included atherosclerosis 29 (57%), Takayasu's arteritis 11(22%), fibromuscular dysplasia six (11%), renal artery dissection two (4%), trauma two(4%¿ and aneurysm one (2%). Fifteen (29%) patients had bilateral renal artery disease, and 16 (31%) had associated chronic renal failure. Seven patients initially underwent percutaneous transluminal angioplasty, three of whom later required operative intervention for recurrent hypertension, and one required repeat angioplasty. Three patients had no further intervention. Forty-seven patients underwent surgical revascularization tailored to the angiographic and intraoperative findings. Procedures performed included 36 (55%) aortorenal bypasses; 12 (18%) endarterectomies; five (8%) ex-vivo reconstructions; three (4%) renal artery reimplantations; two (3%) other visceral artery-to renal (hepatic/splenic) reconstructions; one (2%) renal artery patch graft; and seven (10%) nephrectomies. Concomitant aortic replacement occurred in 20 cases. There were two deaths, and remedial operations for recurrent hypertension were required in three patients. The mean follow up was 12 months (range 6-45 months). Hypertension was cured in 25 (57%), improved in 14(32%), and unchanged in five (11%). Of the 16 patients with chronic renal failure, eight (50%) had a reduction in serum creatinine >10%. The etiology of renovascular hypertension is variable. Although transluminal angioplasty may be indicated in selected patients, surgical revascularization is usually necessary. A flexible operative approach to accommodate the variable patterns of renal artery disease optimizes surgical results. Renal revascularization may provide and improvement in excretory renal function.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app